Celularity (NASDAQ:CELU) Shares Down 7% – Time to Sell?

Celularity, Inc. (NASDAQ:CELU)’s share price dropped 7% on Thursday . The company traded as low as $0.6830 and last traded at $0.6830. 25,290 shares were traded during trading, a decline of 50% from the average session volume of 50,539 shares. The stock had previously closed at $0.7342.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Celularity from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.00.

Celularity Trading Down 7.0%

The business has a fifty day moving average of $0.76 and a 200-day moving average of $1.03. The firm has a market cap of $19.77 million, a PE ratio of -0.21 and a beta of 0.54.

Institutional Investors Weigh In On Celularity

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Celularity by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after acquiring an additional 176,518 shares during the period. Jane Street Group LLC bought a new position in Celularity in the 4th quarter valued at $46,000. Geode Capital Management LLC boosted its holdings in Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after purchasing an additional 20,876 shares during the period. Bank of America Corp DE grew its position in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after purchasing an additional 35,023 shares in the last quarter. Finally, XTX Topco Ltd grew its position in shares of Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after purchasing an additional 11,057 shares in the last quarter. 19.02% of the stock is owned by hedge funds and other institutional investors.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.